GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stimcell Energetics Inc (OTCPK:STME) » Definitions » Altman Z2-Score

STME (Stimcell Energetics) Altman Z2-Score : -1,041.34 (As of Mar. 25, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Stimcell Energetics Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Stimcell Energetics has a Altman Z2-Score of -1,041.34, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Stimcell Energetics's Altman Z2-Score or its related term are showing as below:

STME' s Altman Z2-Score Range Over the Past 10 Years
Min: -3684.91   Med: -455.07   Max: -70.3
Current: -1041.34

During the past 13 years, Stimcell Energetics's highest Altman Z2-Score was -70.30. The lowest was -3684.91. And the median was -455.07.


Stimcell Energetics Altman Z2-Score Historical Data

The historical data trend for Stimcell Energetics's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stimcell Energetics Altman Z2-Score Chart

Stimcell Energetics Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -274.06 -875.15 -1,200.54 -503.48 -860.37

Stimcell Energetics Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,256.84 -464.36 -860.37 -1,834.41 -1,041.34

Competitive Comparison of Stimcell Energetics's Altman Z2-Score

For the Medical Devices subindustry, Stimcell Energetics's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stimcell Energetics's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Stimcell Energetics's Altman Z2-Score falls into.



Stimcell Energetics Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Stimcell Energetics's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-16.5+3.26*-276.3684+6.72*-4.6316+1.05*-0.9628
=-1,041.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Nov. 2024:
Total Assets was $0.04 Mil.
Total Current Assets was $0.04 Mil.
Total Current Liabilities was $0.67 Mil.
Retained Earnings was $-10.50 Mil.
Pre-Tax Income was -0.14 + -0.067 + -0.125 + 0.12 = $-0.21 Mil.
Interest Expense was -0.009 + -0.009 + -0.008 + -0.01 = $-0.04 Mil.
Total Liabilities was $1.02 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.038 - 0.665)/0.038
=-16.5

X2=Retained Earnings/Total Assets
=-10.502/0.038
=-276.3684

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-0.212 - -0.036)/0.038
=-4.6316

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-0.983 - 0)/1.021
=-0.9628

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Stimcell Energetics has a Altman Z2-Score of -1,041.34 indicating it is in Distress Zones.


Stimcell Energetics  (OTCPK:STME) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Stimcell Energetics Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Stimcell Energetics's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Stimcell Energetics Business Description

Traded in Other Exchanges
N/A
Address
1130 Pender Street, West, Suite 820, Vancouver, BC, CAN, V6E 4A4
Stimcell Energetics Inc is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to: aging, diabetes, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
Executives
Richard Jeffs 10 percent owner FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz director, officer: Chief Executive Officer SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves 10 percent owner 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty director, officer: CEO, CFO, Treas., Sec 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta director, officer: COO #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams director 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen director, officer: CEO 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson officer: Chief Medical Officer 9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina officer: CFO, Treasurer and Secretary 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett 10 percent owner 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer director, officer: Chief Technology Officer C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103